Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, Harada T, Harada M, Takamura K, Oizumi S, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Kanazawa K, et al. Among authors: yokouchi h. Cancer Chemother Pharmacol. 2014 Dec;74(6):1149-57. doi: 10.1007/s00280-014-2589-3. Epub 2014 Oct 8. Cancer Chemother Pharmacol. 2014. PMID: 25294632 Clinical Trial.
Elevated serum KL-6 concentrations in patients with diabetes mellitus.
Takahashi T, Takamura K, Sakaue S, Ishii J, Yokouchi H, Nasuhara Y. Takahashi T, et al. Among authors: yokouchi h. J Diabetes Complications. 2002 Sep-Oct;16(5):352-8. doi: 10.1016/s1056-8727(01)00220-3. J Diabetes Complications. 2002. PMID: 12200080
Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.
Konishi J, Yamazaki K, Kinoshita I, Isobe H, Ogura S, Sekine S, Ishida T, Takashima R, Nakadate M, Nishikawa S, Hattori T, Asahina H, Imura M, Kikuchi E, Kikuchi J, Shinagawa N, Yokouchi H, Munakata M, Dosaka-Akita H, Nishimura M. Konishi J, et al. Among authors: yokouchi h. Anticancer Res. 2005 Jan-Feb;25(1B):435-41. Anticancer Res. 2005. PMID: 15816608 Free article.
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M. Asahina H, et al. Among authors: yokouchi h. Br J Cancer. 2006 Oct 23;95(8):998-1004. doi: 10.1038/sj.bjc.6603393. Br J Cancer. 2006. PMID: 17047648 Free PMC article. Clinical Trial.
Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells.
Shinagawa N, Yamazaki K, Tamura Y, Imai A, Kikuchi E, Yokouchi H, Hommura F, Oizumi S, Nishimura M. Shinagawa N, et al. Among authors: yokouchi h. Cancer Immunol Immunother. 2008 Feb;57(2):165-74. doi: 10.1007/s00262-007-0359-3. Epub 2007 Jul 13. Cancer Immunol Immunother. 2008. PMID: 17628800 Free PMC article.
317 results